Abdominal Laparoscopic and/or Robotic SurgeryIPLANCT07775599
Intraperitoneal Lidocaine and Bupivacaine for Postoperative Pain After Laparoscopic Surgery
A study testing Lidocaine and Bupivacaine in people with Abdominal Laparoscopic and/or Robotic Surgery and Local Anasthesia, run by Misr University for Science and Technology at 1 site in Egypt.
Trial summary
The goal of this clinical trial is to determine the safety and efficacy of combined intraperitoneal local anesthetic instillation and port-site infiltration using lidocaine and bupivacaine in adults aged 18 to 60 undergoing elective laparoscopic abdominal surgeries (such as laparoscopic cholecystectomy, appendectomy… Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Abdominal Laparoscopic and/or Robotic Surgery, Local Anasthesia, Post Operative Pain, Acute
- What is being tested?
- Lidocaine and Bupivacaine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 64 participants
- Where
- 1 siteEgypt
- Study dates
- 6 Aug 2025to 5 Jul 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Adults aged 18 to 60 years.
- Scheduled for laparoscopic abdominal surgery (e.g., laparoscopic cholecystectomy, laparoscopic appendectomy, or laparoscopic hernia repair).
- American Society of Anesthesiologists (ASA) physical status I or II.
- No history of chronic pain, opioid dependence, or severe medical comorbidities.
- Able and willing to provide written informed consent.
Who cannot join
- Conversion from laparoscopic to open surgery.
- Acute cholecystitis, gangrene, or empyema of the gallbladder.
- Oncologic or extensive laparoscopic procedures expected to have a prolonged operative time.
- Known allergy or hypersensitivity to lidocaine, bupivacaine, or other local anesthetic agents.
- Diabetes mellitus.
- Current systemic corticosteroid use.
Show all 9Show fewer
- Pregnancy.
- Cardiac, pulmonary, hepatic, or renal disorders.
- History of opioid use or opioid dependence.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Effectiveness of Intraperitoneal Lidocaine and Bupivacaine Instillation for Reducing Postoperative Pain in Laparoscopic Abdominal Surgery: A Randomized Controlled Trial
The goal of this clinical trial is to determine the safety and efficacy of combined intraperitoneal local anesthetic instillation and port-site infiltration using lidocaine and bupivacaine in adults aged 18 to 60 undergoing elective laparoscopic abdominal surgeries (such as laparoscopic cholecystectomy, appendectomy, or hernia repair). The main questions it aims to answer are: Does combined intraperitoneal local anesthetic instillation and port-site infiltration reduce immediate and early (up to 4 hours) postoperative pain scores? Does this intervention reduce the early need for additional postoperative analgesics and shorten the length of hospital stay? Researchers will compare the treatment group receiving lidocaine (2%) and bupivacaine (0.5%) by intraperitoneal instillation and port-site infiltration with a control group receiving normal saline by the corresponding routes to determine whether the local anesthetic intervention reduces postoperative pain and analgesic requirements. Participants will undergo scheduled elective laparoscopic abdominal surgery and receive either the local anesthetic intervention or normal saline during the surgical procedure. Pain will be assessed using the Visual Analog Scale (VAS) immediately after surgery in the recovery room and again at 2 and 4 hours after surgery. Analgesic needs will be monitored and documented, and total hospital stay will be recorded.
- Conditions
- Abdominal Laparoscopic and/or Robotic Surgery, Local Anasthesia, Post Operative Pain, Acute, Lidocaine, Bupivacaine
- Being tested
- Lidocaine, Placebo Normal Saline (NS), Bupivacaine
- Keywords
- Abdominal Laparoscopic Surgery, local anasthesia, Pain, lidocaine, Bupivacaine
- Medical subject headings
- Pain, Postoperative, Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LidocaineDrug
10 mL lidocaine 2% administered intraoperatively by intraperitoneal instillation and port-site infiltration
Placebo Normal Saline (NS)Other
Intraoperative intraperitoneal instillation and port-site infiltration of normal saline
BupivacaineDrug
10 mL bupivacaine 0.5% administered intraoperatively by intraperitoneal instillation and port-site infiltration
| Study group | Role | What they receive |
|---|---|---|
| Local Anesthetic Group | Active comparator | Participants in this arm will receive a total of 20 mL of study solution prepared by combining 10 mL of 2% lidocaine with 10 mL of 0.5% bupivacaine. The resulting 20-mL mixture will be divided equally between the intraperitoneal and port-site routes: 10 mL will be instilled intraperitoneally over the surgical bed, while the remaining 10 mL will be equally distributed among the trocar wounds for port-site infiltration. Receives: Drug: Lidocaine; Drug: Bupivacaine |
| Saline Group | Placebo comparator | Participants in this arm will receive a total of 20 mL of normal saline, divided equally between intraperitoneal instillation and port-site infiltration: 10 mL will instilled intraperitoneally over the surgical bed, while the remaining 10 mL will equally distributed among the trocar wounds. Receives: Other: Placebo Normal Saline (NS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Need for rescue opioid analgesia
Number of participants requiring rescue opioid analgesia for postoperative pain.
Measured: Immediately after surgery, 2 hours after surgery, and 4 hours after surgery
Secondary outcomes (3)
Postoperative pain intensity
Postoperative pain intensity assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, with higher scores indicating greater pain intensity.
Measured: Immediately after surgery, 2 hours after surgery, and 4 hours after surgery
Length of hospital stay
Duration of hospitalization, measured from admission to discharge.
Measured: From admission until hospital discharge (up to 1 week)
Surgery duration
Duration of surgery measured in minutes from anesthesia induction until completion of wound dressing.
Measured: During surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Aug 2026
- Study start6 Aug 2025
- Primary completion5 Jul 2026
- Study completion5 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Abdominal Laparoscopic and/or Robotic SurgeryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Misr University for Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Ahmed Tolba Abdelsalam, Misr University for Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07775599
- Sponsor's protocol ID
- 2025/0099
- Acronym
- IPLA
- Status last verified
- Aug 2026
- First submitted
- 7 Aug 2026
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No